Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] Delta-He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD-1/PD-L1 Inhibitors
    Hong, Green
    Lee, Song-, I
    Kang, Da Hyun
    Chung, Chaeuk
    Park, Hee Sun
    Lee, Jeong Eun
    CANCER MEDICINE, 2025, 14 (07):
  • [22] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [23] Identifying Resistance to Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in NSCLC
    Leal, T.
    Schehr, J.
    Kaminski, A.
    Campbell, T.
    Traynor, A.
    Lang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S160 - S160
  • [24] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [25] PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
    Lau, S.
    Rabindranath, M.
    Weiss, J.
    Li, J.
    Nirmalakumar, S.
    Ruff, H.
    Boerner, S.
    Tong, L. C.
    Tsao, M.
    Pal, P.
    Cabanero, M.
    Hsu, Y. H.
    Fung, A.
    Sacher, A.
    Shepherd, F. A.
    Liu, G.
    Bradbury, P.
    Yasufuku, K.
    Czarnecka-Kujawa, K.
    Ko, H. M.
    Leighl, N.
    Schwock, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S963 - S963
  • [26] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [27] Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
    Costantini, A. E.
    Kamga, P. Takam
    Capron, C.
    Emile, J-F.
    Giroux-Leprieur, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S269 - S270
  • [28] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [29] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    Journal of Hematology & Oncology, 12
  • [30] A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
    Cortellini, Alessio
    Zampacorta, Claudia
    De Tursi, Michele
    Grillo, Lucia R.
    Ricciardi, Serena
    Bria, Emilio
    Martini, Maurizio
    Giusti, Raffaele
    Filetti, Marco
    Dal Mas, Antonella
    Russano, Marco
    Dall'Olio, Filippo Gustavo
    Buttitta, Fiamma
    Marchetti, Antonio
    PATHOLOGICA, 2024, 116 (04) : 222 - 231
12345